On Tuesday, Guggenheim reaffirmed its Buy rating and $170.00 price target on Praxis Precision Medicines Inc. (NASDAQ:PRAX), following the announcement of positive Phase II trial results for its drug relutrigine in treating rare epileptic disorders. The trial, named EMBOLD, showed promising outcomes for patients with SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs).
The study included 16 participants aged 2 to 18 years and reported a significant 46% reduction in monthly motor seizure frequency when adjusted for placebo effects, surpassing the 20-30% benchmark set by management.
The long-term extension of the study revealed a 75% average reduction in seizures among the 8 patients who completed at least 28 days, suggesting the drug's sustained effectiveness.
Furthermore, 5 of the patients, which constitutes 33% of the study group, achieved a 28-day seizure-free period while using relutrigine. This result is particularly notable given the severity of the conditions treated, with patients experiencing more than 50 baseline motor seizures per month.
The safety profile of relutrigine was also highlighted as relatively clean, with the most common adverse effects being infections, vomiting, fever, drowsiness, and constipation, and no patients had to discontinue or reduce the dosage due to adverse events.
The analyst from Guggenheim expressed confidence in the ongoing registrational study for relutrigine based on the safety profile, the drug's concentration to efficacy relationship, and the achievement of seizure freedom. The firm estimates that treating SCN2A and SCN8A DEEs alone could represent a $500 million opportunity for Praxis.
Despite a slight intraday stock decrease of 2.5%, compared to a 2% drop in the XBI, the firm anticipates a 20-40% increase in Praxis's stock value today and recommends purchasing shares, especially given the current market weakness.
In other recent news, Praxis Precision Medicines has made significant strides in the medical field with promising results from their recent clinical studies. The company's Phase 2 EMBOLD study on relutrigine, a sodium channel inhibitor, showed a notable reduction in seizures among participants.
The results prompted Truist Securities to maintain their Buy rating and a $150.00 stock price target for the company, highlighting the broad potential of relutrigine across a spectrum of epilepsies.
Various analyst firms have shown interest in Praxis Precision Medicines' progress. Piper Sandler maintained an Overweight rating with a price target of $270.00, while H.C. Wainwright raised its price target to $120, and Guggenheim maintained a Buy rating and increased the price target to $170. Oppenheimer initiated coverage on Praxis Precision with an Outperform rating, citing the potential of the company's central nervous system drugs.
In addition to the advancements in epilepsy treatment, Praxis Precision Medicines has also been proactive in their clinical trials. The company's upcoming interim Essential3 Part1 analysis, expected in the fourth quarter of 2024, and the anticipated release of the relutrigine EMBOLD data in the third quarter of 2024, were highlighted in their recent second-quarter earnings call.
InvestingPro Insights
As Praxis Precision Medicines Inc. (NASDAQ:PRAX) garners attention with its positive Phase II trial results, a glance at the company's financial health and market performance offers additional insights. According to InvestingPro data, Praxis holds a market capitalization of approximately $941.48 million. Despite the promising clinical outcomes, the company's financials reflect a challenging landscape, with a negative P/E ratio of -5.44, indicating that it is not currently profitable. This is further underscored by a gross profit margin of -4975.78% over the last twelve months as of Q2 2024, suggesting significant costs relative to revenues during this period.
InvestingPro Tips also reveal that analysts have mixed views on the company's near-term prospects. While six analysts have revised their earnings upwards for the upcoming period, suggesting optimism about Praxis's future performance, they also anticipate a sales decline in the current year and do not expect the company to be profitable this year. However, it's worth noting that Praxis's stock price has seen a high return over the last year, with a year-to-date price total return of 138.55%, which may interest investors looking for growth potential in their portfolio.
For a more comprehensive analysis, there are additional InvestingPro Tips available for Praxis, which can be explored for deeper investment insights. This includes the company's liquidity position, with liquid assets exceeding short-term obligations, and its cash holdings, which are greater than its debt, potentially providing a buffer against financial headwinds.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.